Anifrolumab shows higher remission rates versus placebo in SLE patients regardless of immunosuppressant history
A New Lupus Drug May Work Better If You Start It Sooner
A post hoc analysis of pooled Phase 3 RCT data in 726 patients with moderate-to-severe SLE found higher DORIS remission rates with anifrolum…
Starting a new lupus drug before trying older medications may help patients reach remission faster and with fewer side effects.
Hydroxychloroquine did not prevent SLE progression in incomplete lupus patients in randomized trial
Hydroxychloroquine did not slow disease progression in incomplete lupus patients over two years
A randomized, double-blind trial of 180 patients with incomplete lupus erythematosus found hydroxychloroquine did not reduce progression to …
Hydroxychloroquine failed to slow lupus progression in patients with early symptoms over two years, matching placebo results.
IFN-I signature correlates with alloimmunization transcriptomic programs in SLE patients
Could a common lupus signal reveal who's at risk for transfusion complications?
An observational cohort analysis of 150 SLE patients from three RNA-seq cohorts found a significant positive correlation between Type I inte…
A high Type I interferon signal in lupus patients strongly predicts genetic markers linked to dangerous immune reactions to blood transfusio…
Peer mentoring shows non-significant symptom reduction in African American women with SLE
Peer mentoring shows potential for lupus symptoms in African American women
A randomized controlled trial sub-analysis in adult African American women with SLE found that a 12-session peer-mentoring intervention led …
A study tested whether peer mentoring could help African American women with lupus manage their symptoms.
Meta-analysis finds elevated neutrophil-to-lymphocyte ratio in SLE, with weak correlation to disease activity
Can a simple blood test help track lupus activity? The evidence is mixed
A meta-analysis of 40 studies with external validation (n=290) found neutrophil-to-lymphocyte ratio (NLR) was higher in SLE patients versus …
A simple blood ratio tracks lupus activity better than healthy levels, but its accuracy varies by ethnicity and treatment, so it isn't ready…
LOC100130476 rs80213143 variant associated with SLE susceptibility and renal involvement in Chinese Han cohort
Genetic variant linked to lupus susceptibility and kidney involvement in Chinese study
A cohort study in a Chinese Han population found the rs80213143 variant at LOC100130476 was associated with systemic lupus erythematosus sus…
A specific genetic marker found in Chinese patients is strongly linked to lupus and predicts more severe kidney disease.
Review examines glucose metabolic reprogramming in SLE and lupus nephritis pathogenesis
Review explores how sugar metabolism changes might fuel lupus immune system problems
A systematic review synthesizes evidence on glucose metabolic reprogramming in immune cells in systemic lupus erythematosus and lupus nephri…
Lupus immune cells change how they use sugar for energy, a shift that drives the disease and kidney damage, opening doors to new metabolic t…
Perspective highlights diagnostic overlap between idiopathic multicentric Castleman disease and systemic lupus erythematosus
Castleman disease can resemble lupus, requiring careful diagnosis for proper treatment
A perspective article discusses the clinical resemblance between idiopathic multicentric Castleman disease (iMCD) and systemic lupus erythem…
Castleman disease often mimics lupus with shared symptoms and autoantibodies, but misdiagnosis risks wrong treatment until a lymph node biop…
Phase 3 Trial of Cenerimod for Lupus Nephritis: Efficacy and Safety Evaluation
Could a New Drug Help Improve Kidney Function in Lupus Patients?
A Phase 3 trial is assessing cenerimod's efficacy and safety in treating active lupus nephritis. The primary endpoint is complete renal resp…
A new trial tests whether adding cenerimod to regular treatment can improve kidney function in adults with active lupus nephritis over 76 we…
Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary Outcome
Could a New Treatment Offer Hope for Patients with Lupus?
In a Phase 3 trial with 367 SLE patients, subcutaneous anifrolumab was tested against placebo. The primary endpoint is the BICLA response, b…
A new subcutaneous treatment is being tested to help adults with moderate to severe lupus who aren't responding well to standard care.
Questions about Systemic Lupus Erythematosus
How do biologics compare to targeted drugs for treating systemic lupus erythematosus?
Biologics (e.g., anifrolumab, belimumab) and targeted drugs (e.g., telitacicept, upadacitinib) both treat SLE, but network meta-analyses show telitacicept may outperform belimumab for SRI-4 response, while anifrolumab and deucravacitinib work better for skin symptoms. Safety prof
Full answer →How common is female sexual dysfunction in women with systemic lupus erythematosus according to recent studies?
Recent studies show that about 59% of women with systemic lupus erythematosus experience sexual dysfunction, which is significantly higher than in healthy women.
Full answer →